Infections and atherosclerosis: New clues from an old hypothesis?

American Journal of Epidemiology

Volumn 148, Issue 10, 1998, Pages 937-948

  Nieto, F Javier ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROGENESIS; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE ASSOCIATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFECTION; NOTE; RISK ASSESSMENT; RISK FACTOR; SMOKING;

EID: 3643143768     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a009570     Document Type: Note

References (137)

1. Braunwald E. Shattuck lecture - cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997;337:1360-9.
2. Hennekens CH. Increasing burden of cardiovascular disease. Current knowledge and future directions for research on risk factors. Circulation 1998;97:1095-1102.
3. Melnick JL, Adam E, DeBakey ME. Possible role of cytomegalovirus in atherogenesis. JAMA 1990;263:2204-7.
4. Grayston JT, Kuo C, Campbell LA, et al. Chlamydia pneumoniae strain, TWAR and atherosclerosis. Eur Heart J 1993; 14(Suppl K):66-71.
5. Nieminen MS, Manila K, Valtonen V. Infection and inflammation as risk factors for myocardial infarction. Eur Heart J 1993;14(Suppl K):12-16.
6. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997;350:430-6.
7. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis. An assessment of the evidence and need for future research. Circulation 1997;96: 4095-4103.
8. Nicholson AC, Hajjar DP. Herpesvirus in atherosclerosis and thrombosis: etiologic agents or ubiquitous bystanders? Arterioscler Thromb Vasc Biol 1998;18:339-48.
9. Mehta JL, Saldeen TGP, Rand K. Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease. J Am Coll Cardiol 1998; 31:1217-25.
10. Mattila KJ, Valtonen VV, Nieminen MS, et al. Role of infection a risk factor for atherosclerosis, myocardial infarction, and stroke. Clin Infect Dis 1998;26:719-34.
11. Cunningham MJ, Pasternak RC. The potential role of viruses in the pathogenesis of atherosclerosis. Circulation 1988;77: 964-6.
12. Wissler RW. Significance of Chlamydia pneumoniae (TWAR) in atherosclerotic lesions. (Editorial). Circulation 1995;92:3376.
13. Gupta S, Leatham EW. The relation between Chlamydia pneumoniae and atherosclerosis. (Editorial). Heart 1997;77: 7-8.
14. Lip GYH, Beevers DG. Can we treat coronary artery disease with antibiotics? Lancet 1997;350:378-9.
15. Ridker PM. Inflammation, infection, and cardiovascular risk. How good is the clinical evidence? Circulation 1998;97: 1671-4.
16. Grayston JT. Antibiotic treatment of Chlamydia pneumoniae for secondary prevention of cardiovascular events? Circulation 1998;97:1669-70.
17. Lilienfeld AM. Epidemiology of infectious and non-infectious disease. Some comparisons. Am J Epidemiol 1973;97: 135-47.
18. Evans AS. Causation and disease. A chronological journey. New York: Plenum Medical Book Co, 1993.
19. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
20. Munro JM, Cotran RS. The pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab Invest 1988;58: 249-61.
21. Alexander RW. Inflammation and coronary artery disease (Editorial). N Engl J Med 1994;331:468-9.
22. Kuller LH, Tracy RP, Shaten J, et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol 1996;144:537-47.
23. Maseri A. Inflammation, atherosclerosis and ischemic events - Exploring the hidden side of the moon. (Editorial). N Engl J Med 1997;336:1014-16.
24. Rayer P. Mémoire sur l'ossification morbide, considérée comme une terminaison des phlegmasies. Arch Gén Méd J (Paris) 1923:1:313-35.
25. Rokitansky C. A manual of pathological anatomy. (English translation of German edition). Philadelphia, PA: Blanchard and Lea, 1855:4:201-8.
26. Virchow R. Cellular pathology as based upon physiological and pathological histology. (English translation of second German edition). Philadelphia, PA: JB Lippincott, 1971.
27. Karsner HT, Bayless F. Coronary arteries in rheumatic fever. Am Heart J 1934;9:557-85.
28. Saphir O, Gore I. Evidence of an inflammatory basis of coronary arteriosclerosis in the young. Arch Pathol 1950;49: 418-26.
29. Joris I, Majno G. Atherosclerosis and inflammation. Adv Exp Med Biol 1977;104:227-33.
30. Boinet É, Romary Dr. Recherches expérimentales sur les aortites. Arch Médicine Expérimentale 1897;9:902-30.
31. Thayer WS. On the late effects of typhoid fever on the heart and vessels. Am J Med Sci 1904;77:391-422.
32. Frothingham C. The relation between acute infectious diseases and arterial lesions. Arch Intern Med 1911;8:153-62.
33. Gilbert A, Lion G. Artérites infectieuses expérimentales. Comptes Rendus Hebdomadaires des Séances et Mémoires de la Société de Biologie 1889;41:583-4.
34. Crocq JJ. Contribution a l'étude expérimentale des artérites infectieuses. Arch Médicine Expérimentale 1894;6:583-600.
35. Thayer WS, Brush CE. The relation of acute infections and arteriosclerosis. JAMA 1904;43:726-9.
36. Osler W. Diseases of the arteries. In: Osler W, MacCrae T, eds. Modern medicine. Its theory and practice in original contributions by Americans and foreign authors. Vol 4. Philadelphia, PA: Lea & Fabiger, 1908:426-47.
37. MacCallum WG. Acute and chronic infections as etiological factors in arteriosclerosis. In: Cowdry EV, ed. Arteriosclerosis. A survey of the problem. New York: MacMillan Co, 1933:355-62.
38. Klotz O. Fatty degeneration of the intima of arteries. J Med Res 1915;32:27-43.
39. Klotz O. A discussion on the classification and experimental production of arteriosclerosis. BMJ 1906;2:1767-72.
40. Susser M, Susser E. Choosing a future for epidemiology: I. Eras and paradigms. Am J Public Health 1996;86:668-73.
41. Ophüls W. Arteriosclerosis and cardiovascular disease. Their relation to infectious diseases. JAMA 1921;76:700-1.
42. Benson RL, Smith KG, Semenov H. Experimental arteritis and arteriosclerosis associated with streptococcal inoculations. Arch Pathol 1931;12:924-40.
43. Jones NW, Rogers AL. The incidence of sptreptoccal infection in cardiovascular sclerosis. Ann Intern Med 1935;8: 834-53.
44. Jones NW, Rogers AL. Chronic infections and atherosclerosis. Arch Pathol 1948;45:271-7.
45. Benditt EP, Benditt JM. Evidence of a monoclonal origin of human atherosclerotic plaques. Proc Nat Acad Sci USA 1973;70:1753-6.
46. Martin GM, Sprague CA, Norwood TH, et al. Clonal selection, attenuation and differentiation in an in vitro model of hyperplasia. Am J Pathol 1974;74:137-54.
47. Pearson TA, Wang BA, Solez K, et al. Clonal characteristics of fibrous plaques and fatty streaks from human aortas. Am J Pathol 1975;81:379-87.
48. Pearson TA, Dillma JM, Solez K, et al. Clonal characteristics of cutaneous scars and implications for atherogenesis. Am J Pathol 1981;102:49-54.
49. Virus infections and atherosclerosis. (Editorial). Lancet 1078;2:821-2.
50. Fabricant CG, Fabricant J, Litrenta MM, et al. Virus-induced atherosclerosis. J Exp Med 1978;148:335-40.
51. Fabricant CG, Fabricant J, Minick CR, et al. Herpesvirus-induced atherosclerosis in chickens. Fed Proc 1983;42: 2476-9.
52. Laitinen K, Laurila A, Pyhälä L, et al. Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect Immun 1997;65:4832-5.
53. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998;97:633-6.
54. Saikku P, Wang SP, Kleemola M, et al. An epidemic of mild pneumonia due to an unusual strain of Chlamydia psittaci. J Infect Dis 1985;151:832-9.
55. Grayston JT, Campbell LA, Kuo C, et al. A new respiratory tract pathogen: Chlamydia pneumoniae strain, TWAR. J Infect Dis 1990;161:618-25.
56. Moazed TC, Kuo CC, Grayston JT, et al. Murine models of Chlamydia pneumoniae infection in atherosclerosis. J Infect Dis 1997;175:883-90.
57. Zhou YF, Shou M, Harrell RL, et al. Effect of latent cytomegalovirus infection of rats on the neointimal response to vascular balloon injury. (Abstract). J Am Coll Cardiol 1997; 29(Suppl A):420A.
58. Fabricant CG, Krook L, Gillespie JH. Virus-induced cholesterol crystals. Science 1973;181:566-7.
59. Yamashiroya HM, Ghosh L, Yang R, et al. Herpesviridae in the coronary arteries and aorta of young trauma victims. Am J Pathol 1988;130:71-9.
60. Lopes-Virella MF, Virella G. Immunological and microbiological factors in the pathogenesis of atherosclerosis. Clin Immunol Immunopathol 1985;37:377-86.
61. Span AHM, Van Boven CPA, Bruggeman CA. The effect of cytomegalovirus infection on the adherence of polymorphonuclear leukocytes to endothelial cells. Eur J Clin Invest 1989;19:542-8.
62. Zajac BA, O'Neill K, Friedman HM, et al. Increased adherence of human granulocytes to herpes simplex virus type 1 infected endothelial cells. In Vitro Cell Dev Biol 1988;24: 321-5.
63. Shahgasempour S, Woodroffe SB, Garnett HM. Alterations in the expression of ELAM-1, ICAM-1 and VCAM-1 after in vitro infection of endothelial cells with a clinical isolate of human cytomegalovirus. Microbiol Immunol 1997;41: 121-9.
64. Hajjar DP, Fabricant CG, Minick CR, et al. Virus induced atherosclerosis. Herpesvirus infection alters aortic cholesterol metabolism and accumulation. Am J Pathol 1986;122: 62-70.
65. Zhou Y, Guetta E, Yu Z, et al. Human cytomegalovirus increases modified low density lipoprotein uptake and scavenger receptor mRNA expression in vascular smooth muscle cells. J Clin Invest 1996;98:2129-38.
66. Speir E, Modali R, Huang ES, et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 1994;265:391-4.
67. Zhu H, Shen Y, Shenk T. Human cytomegalovirus IE1 and IE2 proteins block apoptosis. J Virol 1995;69:7960-70.
68. Kovacs A, Weber ML, Burns LJ, et al. Cytoplasmic sequestration of p53 in cytomegalovirus-infected human endothelial cells. Am J Pathol 1996;149:1531-9.
69. Bruggeman CA, Debie WHM, Muller AD, et al. Cytomegalovirus alters the von Willebrand factor content in human endothelial cells. Thromb Haemost 1988;59:264-8.
70. van Dam-Mieras MCE, Muller AD, van Hinsbergh VWM, et al. The procoagulant response of cytomegalovirus infected endothelial cells. Thromb Haemost 1992;68:364-70.
71. Etingin OR, Silverstein RL, Friedman HM, et al. Viral activation of the coagulation cascade: molecular interactions at the surface of infected endothelial cells. Cell 1990;61: 657-62.
72. Vercellotti GM. Proinflammatory and procoagulant effects of herpes simplex infection on human endothelium. Blood Cells 1990;16:209-16.
73. Pryzdial ELG, Wright JF. Prothrombinase assembly on an enveloped virus: evidence that the cytomegalovirus surface contains procoagulant phospholipid. Blood 1994;11: 3749-57.
74. Fryer RH, Schwobe EP, Woods ML, et al. Chlamydia species infect human vascular endothelial cells and induce procoagulant activity. J Invest Med 1997;45:168-74.
75. Halme S, Syrjälä H, Bloigu A, et al. Lymphocyte responses to Chlamydia antigens in patients with coronary heart disease. Eur Heart J 1997;18:1095-1101.
76. Tumilowicz JJ, Gawlil ME, Powell BB, et al. Replication of cytomegalovirus in human arterial smooth muscle cells. J Virol 1985;56:839-45.
77. Gaydos CA, Summersgill JT, Sahney NN, et al. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun 1996;64:1614-20.
78. Span AHM, Mullers W, Miltenburg AM, et al. Cytomegalovirus induced PMN adherence in relation to an ELAM-1 antigen present on infected endothelial cell monolayers. Immunology 1991;72:355-60.
79. Allen MD, MacDonald TO, Carlos T, et al. Endothelial adhesion molecules in heart transplantation. J Heart Lung Transplant 1992;11:S8-S13.
80. Kaukoranta-Tolvanen SS, Teppo AM, Laitinen K, et al. Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. Microb Pathog 1996;21:215-21.
81. Ong G, Thomas BJ, Mansfield AO, et al. Detection and widespread distribution of Chlamydia pneumoniae in the vascular system and its possible implications. J Clin Pathol 1996;49:102-6.
82. Sammalkorpi KT, Valtonen VV, Maury CPJ. Lipoproteins and acute phase response during acute infection. Interrelationships between C-reactive protein and serum amyloid-A protein and lipoproteins. Ann Med 1990;22:397-401.
83. Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet 1997;349:1391-2.
84. Théroux P, Fuster V. Acute coronary syndromes. Unstable angina and non-Q-wave myocardial infarction. Circulation 1998;97:1195-1206.
85. Xu Q, Willeit J, Marosi M, et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet 1993;341:255-9.
86. Wick G, Romen M, Amberger A, et al. Atherosclerosis, autoimmunity, and vascular-associated lymphoid tissue. FASEB J 1997;11:1199-1207.
87. Kol A, Sukhova GK, Lichtman AH, et al. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-α and matrix metalloproteinase expression. Circulation 1998;98:300-7.
88. Beck J, Garcia R, Heiss G, et al. Periodontal disease and cardiovascular disease. J Periodontol 1996;67:1123-37.
89. Adam E, Melnick JL, Probtsfield JL, et al. High level of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis. Lancet 1987;2:291-3.
90. Saikku P, Leinonen M, Mattila K, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988;2:983-6.
91. Zhou YF, Leon MB, Waclawiw MA, et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 1996; 335:624-30.
92. Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989;261:3561-6.
93. Jousilahti P, Vartiainen E, Toumilehto J, et al. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet 1996;348:567-72.
94. Saikku P, Leinonen M, Tenkanen L, et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992;116:273-8.
95. Nieto FJ, Adam E, Sorlie P, et al. Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation 1996;94:922-7.
96. Kark JD, Leinonen M, Paltiel O, et al. Chlamydia pneumoniae and acute myocardial infarction in Jerusalem. Int J Epidemiol 1997;26:730-8.
97. Adler SP, Hur JK, Wang JB, et al. Prior infection with cytomegalovirus is not a major risk factor for angiographically demonstrated coronary artery atherosclerosis. J Infect Dis 1998;177:209-12.
98. Saikku P. The epidemiology and significance of Chlamydia pneumoniae. J Infect 1992;25(Suppl I):27-34.
99. Gershon AA, Gold E, Nankervis GA. Cytomegalovirus. In: Evans AS, Kaslow RA, eds. Viral infections in humans. Epidemiology and control. New York: Plenum Medical Book Co, 1997:229-51.
100. Gulizia JM, Kandolf R, Kendall TJ, et al. Infrequency of cytomegalovirus genome in coronary arteriopathy of human heart allografts. Am J Pathol 1995;147:461-75.
101. Campbell LA, O'Brien ER, Cappuccio AL, et al. Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. J Infect Dis 1995;172:585-8.
102. Chiu B, Viira E, Tucker W, et al. Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery. Circulation 1997;96:2144-8.
103. Melnick JL, Hu C, Burek J, et al. Cytomegalovirus DNA in arterial walls of patients with atherosclerosis. J Med Virol 1994;42:170-4.
104. Blasi F, Denti F, Erba M, et al. Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms. J Clin Microbiol 1996;34: 2766-9.
105. Folsom AR, Nieto FJ, Sorlie P, et al. Helicobacter pylori seropositivity and coronary heart disease incidence. Circulation 1998;98:845-50.
106. Gupta S, Leatham EW, Carrington D, et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997;96:404-7.
107. Gurfinkel E, Bozovich G, Daroca A, et al. Randomized trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997;350:404-7.
108. Sartwell PE. "On the methodology of investigations of etiologic factors in chronic diseases" - Further comments. J Chronic Dis 1960;11:61-3.
109. Rose G. Causes of the trends and variations in CHD mortality in different countries. Int J Epidemiol 1989;18(Suppl 1):S174-S179.
110. Goldberg RJ. Temporal trends and declining mortality rates from coronary heart disease in the United States. In: Ockene IS, Ockene JK, eds. Prevention of coronary heart disease. Boston: Little, Brown & Co, 1992:41-68.
111. Marmot M. Coronary heart disease: rise and fall of a modern epidemic. In: Marmot M, Elliot P. Coronary heart disease epidemiology. From aetiology to public health. New York: Oxford University Press, 1992:3-19.
112. Higgins M, Thom T. Trends in CHD in the United States. Int J Epidemiol 1989;18:S58-S66.
113. Böttcher HM. Miracle drugs. A history of antibiotics. London: Heinemann, 1963.
114. Wainwright M. Miracle cure. The story of penicillin and the golden age of antibiotics. Cambridge, MA: Basil Blackwell, 1990.
115. Anestad G, Scheel O, Hungnes O. Chronic infections and coronary heart disease. (Letter). Lancet 1997;350:1028-9.
116. Eyer J. Changing trends in ischemic heart disease: relations to cohort experience and economic trends in industrial countries. Adv Cardiol 1982;29:50-5.
117. Diez-Roux AV, Nieto FJ, Tyroler HA, et al. Social inequalities and atherosclerosis: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 1995;141;960-72.
118. Rose G, Marmot MG. Social class and coronary heart disease. Br Heart J 1981;45:13-9.
119. Lynch JW, Kaplan GA, Cohen RD, et al. Do cardiovascular risk factors explain the relation between socioeconomic status, risk of all-cause mortality, cardiovascular mortality, and acute myocardial infarction? Am J Epidemiol 1996;144: 934-42.
120. Malaty HM, Graham DY. Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection. Gut 1994;35:742-5.
121. Fall CHD, Vijayakumar M, Barker DJP, et al. Weight in infancy and prevalence of coronary heart disease in adult life. BMJ 1995;310:17-9.
122. Osmond C, Barker DJP, Winter PD, et al. Early growth and death from cardiovascular disease in women. BMJ 1993;307: 1519-24.
123. Barker DJP. Intrauterine programming of coronary heart disease and stroke. Acta Paediatr Suppl 1997;423:178-82.
124. Joseph KS, Kramer MS. Review of the evidence on fetal and early childhood antecedents of adult chronic disease. Epidemiol Rev 1996;18:158-74.
125. Buck C, Simpson H. Infant diarrhoea and subsequent mortality from heart disease and cancer. J Epidemiol Community Health 1982;36:27-30.
126. Weed DL, Hursting SD. Biologic plausibility in causal inference: current method and practice. Am J Epidemiol 1998;147:415-25.
127. Sutter MC. Lessons for atherosclerosis research from tuberculosis and peptic ulcer. Can Med Assoc J 1995;152:667-70.
128. Aschoff L. Introduction. In: Cowdry EV, ed. Arteriosclerosis. A survey of the problem. New York: Macmillan Co, 1933:1-18.
129. Anitschkow N, Chalatow S. Uber experimentelle cholesterinsteatose und ihre bedeutung fur die entstehung einiger pathologische prozesse. Zentralbl Allg Pathol 1913;24:1-9.
130. Keys A. Coronary heart disease - the global picture. Atherosclerosis 1975;22:149-92.
131. Kannel WB, Dawber TR, Kagan A, et al. Factors of risk in the development of coronary heart disease - six-year follow-up experience: the Framingham Study. Ann Intern Med 1961;55:33-50.
132. Goldberg RJ. Coronary heart disease: epidemiology and risk factors. In: Ockene IS, Ockene JK, eds. Prevention of coronary heart disease. Philadelphia, PA: Little, Brown and Co, 1992:3-39.
133. Thom DH, Grayston JT, Siscovick DS, et al. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA 1992;268:68-72.
134. Nieto FJ, Sorlie P, Comstock GW, et al. Cytomegalovirus infection, lipoprotein(a), and hypercoagulability: an atherogenic link? Arterioscler Thromb Vasc Biol 1997;17:1780-5.
135. Dahlen GH, Boman J, Birgander L, et al. Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary disease. Atherosclerosis 1995;114:165-74.
136. Plotkin SA. Vaccines for varicella-zoster virus and cytomegalovirus: recent progress. Science 1994;265:1383-5.
137. Adler SP. Current prospects for immunization against cytomegaloviral disease. Inf Agents Dis 1996;5:29-35.